Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Breast Cancer

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Breast Cancer Res Treat.

Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG)

doi: 10.1007/s10549-018-4783-1.

Breast Cancer

Breast Cancer Treatment in the Era of Precision Medicine

1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland

Further Publications

Clinical implications of food-drug interactions with small-molecule kinase inhibitors

Lancet Oncol.

Veerman GDM, Hussaarts KGAM, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ

doi: 10.1016/S1470-2045(20)30069-3.

RECOMMENDED

Breast Cancer

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition

Eur J Cancer.

Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP

doi: 10.1016/j.ejca.2019.10.024.

Gastrointestinal CancerFurther Publications

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

★ 3 Recommended and commented by Alexander Meisel, Faculty Member

healthbook TIMES Oncology Hematology

Corresponding author: Dr Alexander Siebenhüner Senior Consultant in Medical Oncology Cantonal Hospital Schaffhausen Schaffhausen, Switzerland

SPECIAL REPORT

Breast Cancer

Olaparib confers benefit in metastatic breast cancer

doi: 10.1093/annonc/mdz012. [Epub ahead of print].

Further Publications

Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions

★ 3 Recommended and commented by Alexander Meisel, Faculty Member

1Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland *equal contribution

Breast Cancer

Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis

J Natl Cancer Inst.

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D

doi: 10.1093/jnci/djaa071.

Related content

Recent Developments in Metastatic Breast Cancer

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Breast Cancer Treatment in the Era of Precision Medicine

Clinical implications of food-drug interactions with small-molecule kinase inhibitors

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

Olaparib confers benefit in metastatic breast cancer

Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions

Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis